Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.69 |
| ▸ | QDPR | P09417 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.46 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1470460 | 0.98 | HTR2C (0.69) | HTR2CQDPRSIGMAR1P2RY14HTR6 | |
| SCHEMBL17232840 | 0.84 | HTR2C (0.71) | HTR2CQDPRSIGMAR1P2RY14ALOX5AP | |
| SCHEMBL1813790 | 0.83 | HTR2C (0.49) | HTR2CQDPRSIGMAR1P2RY14HTR6 | |
| Hydrochloric Acid SCHEMBL17222909 | 0.82 | HTR2C (0.72) | HTR2CQDPRSIGMAR1P2RY14HTR6 | |
| SCHEMBL186156 | 0.82 | HTR2C (1.00) | HTR2CQDPRSIGMAR1P2RY14 | |
| SCHEMBL15317711 | 0.81 | HTR2C (0.59) | HTR2CQDPRSIGMAR1P2RY14NISCH | |
| Hydrochloric Acid SCHEMBL1975639 | 0.80 | HTR2C (1.00) | HTR2CQDPRSIGMAR1P2RY14ALOX5AP | |
| Hydrochloric Acid SCHEMBL8905717 | 0.80 | HTR2C (1.00) | HTR2CQDPRSIGMAR1P2RY14ALOX5AP | |
| SCHEMBL23578478 | 0.80 | HTR6 (0.48) | HTR2CQDPRSIGMAR1P2RY14HTR6 | |
| SCHEMBL4847462 | 0.79 | HTR2C (0.47) | HTR2CQDPRSIGMAR1P2RY14HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081509-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | Zydus Lifesciences Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021130723-A1 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | CADILA HEALTHCARE LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-1805158-B1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS INC (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7915253-B2 | 4-[2,6-Dimethyl-4-(4-trifluoromethoxy-phenyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid; peroxisome proliferator activated receptors modulator; antidiabetic, antiinflammatory agent; obesity, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome, ischemia-associated organ injury | KALYPSYS, INC (US) | 2011-03-29 | — | — | US | disclosed |
| US-7834004-B2 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR | KALYPSYS, INC (US) | 2010-11-16 | — | — | US | disclosed |
| EP-1226137-B8 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| EP-1226137-B1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI SYNTHELABO (FR) | 2004-07-21 | — | — | EP | disclosed |
| WO-2004058727-A1 | SUBSTITUTED 3,5-DIHYDRO-4H-IMIDAZOL-4-ONES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003101381-A2 | 1,2 DIAMIDO CYCLOALKYL SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-6509351-B1 | A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation | SANOFI-SYNTELABO (FR) | 2003-01-21 | — | — | US | disclosed |
| EP-1226137-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2002-07-31 | — | — | EP | disclosed |
| US-6303593-B1 | FOR THERAPY HUMAN IMMUNODEFICIENCY VIRUS INFECTION, AQUIRED IMMUNODEFICIENCY SYNDROME (AIDS), INFLAMMATORY AND IMMUNOREGULATORY DISORDER OR DISEASE, ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS | MERCK & CO., INC. | 2001-10-16 | — | — | US | disclosed |
| WO-2001029026-A1 | PHENYL- AND PYRIDYL-TETRAHYDRO-PYRIDINES HAVING TNF INHIBITING ACTIVITY | SANOFI-SYNTHELABO (FR) | 2001-04-26 | — | — | WO | disclosed |
| WO-2000051608-A1 | 3-THIENYL AND 3-FURANYL PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-3936464-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1976-02-03 | — | — | US | disclosed |